D3 Human Dopamine GPCR GTPgammaS Agonist & Antagonist LeadHunter Assay - TW

Procedure Summary:

Human recombinant dopamine D3 receptors stably expressed in CHO-K1 cells are used. Test compound and/or vehicle is preincubated with the membranes (0.04 mg/ml‡) and 1 µM GDP in modified HEPES pH 7.4 buffer for 20 minutes at RT and SPA beads are then added for another 60 minutes at 30°C. The reaction is initiated by 0.3 nM [35S]GTPgS for an additional 30 minute incubation period. Test compound-induced increase of [35S]GTPgS binding by 50 percent or more (≥50%) relative to the 1 µM dopamine response indicates possible dopamine D3 receptor agonist activity. Test compound-induced inhibition of 0.05 μM dopamine-induced increase of [35S]GTPgS binding response by 50 percent or more (≥50%) indicates receptor antagonist activity. Note: ‡Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary.

Incubation:

30 min at 30°C

Control Inhibitor:

Spiperone

Control Activator:

Dopamine

Criteria For Significance:

≥ 50% Increase in bound [35S]GTPgammaS relative to dopamine response, ≥ 50% Inhibition of dopamine-induced bound [35S]GTPgammaS

Test Concentration / Dose:

Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM

Test Sample Requirements:

75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)

Minimum Order Quantity:

16